Dermapharm 

€45.85
50
-€0.65-1.4% Today

Statistics

Day High
46.1
Day Low
44.6
52W High
46.5
52W Low
32.05
Volume
0
Avg. Volume
28
Mkt Cap
0
P/E Ratio
-
Dividend Yield
1.94%
Dividend
0.89

Upcoming

Dividends

1.94%Dividend Yield
Jul 25
€0.9
Jul 24
€0.88
Jun 23
€1.05
Jun 21
€0.88
Jun 19
€0.77
10Y Growth
N/A
5Y Growth
0.45%
3Y Growth
-5.01%
1Y Growth
N/A

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.36
0.5
0.63
0.77
Expected EPS
N/A
Actual EPS
N/A

Financials

9.64%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
2.36BRevenue
227.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMP.VI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates in the pharmaceuticals sector, competing with Dermapharm in various therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a wide range of products that compete with Dermapharm's offerings in the healthcare market.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading pharmaceutical company that develops medicines, vaccines, biologic therapies, and animal health products, competing with Dermapharm in several areas.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline is a global healthcare company that produces pharmaceuticals and vaccines, directly competing with Dermapharm in the healthcare and pharmaceutical sectors.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diversified healthcare company that produces pharmaceuticals, medical devices, and consumer health products, competing with Dermapharm across multiple segments.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global biopharmaceutical company focused on human health, directly competing with Dermapharm in the pharmaceutical and healthcare sectors.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a biopharmaceutical company that develops and markets therapies focused on treating serious medical conditions, competing with Dermapharm in the healthcare sector.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a healthcare company that operates in pharmaceuticals and diagnostics, competing with Dermapharm in the development and marketing of pharmaceutical products.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines, competing with Dermapharm in the generic pharmaceuticals market.

About

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
Show more...
CEO
ISIN
DE000A2GS5D8

Listings

0 Comments

Share your thoughts

FAQ

What is Dermapharm stock price today?
The current price of DMP.VI is €45.85 EUR — it has decreased by -1.4% in the past 24 hours. Watch Dermapharm stock price performance more closely on the chart.
What is Dermapharm stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dermapharm stocks are traded under the ticker DMP.VI.
When is the next Dermapharm earnings date?
Dermapharm is going to release the next earnings report on May 13, 2026.
What were Dermapharm earnings last quarter?
DMP.VI earnings for the last quarter are 0.41 EUR per share, whereas the estimation was 0.41 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Dermapharm revenue for the last year?
Dermapharm revenue for the last year amounts to 2.36B EUR.
What is Dermapharm net income for the last year?
DMP.VI net income for the last year is 227.57M EUR.
Does Dermapharm pay dividends?
Yes, DMP.VI dividends are paid annual. The last dividend per share was 0.9 EUR. As of today, Dividend Yield (FWD)% is 1.94%.
When did Dermapharm complete a stock split?
Dermapharm has not had any recent stock splits.